194 related articles for article (PubMed ID: 18613292)
1. Genetic testing in familial melanoma: uptake and implications.
de Snoo FA; Riedijk SR; van Mil AM; Bergman W; ter Huurne JA; Timman R; Bertina W; Gruis NA; Vasen HF; van Haeringen A; Breuning MH; Tibben A
Psychooncology; 2008 Aug; 17(8):790-6. PubMed ID: 18613292
[TBL] [Abstract][Full Text] [Related]
2. Hereditary melanoma and predictive genetic testing: why not?
Riedijk SR; de Snoo FA; van Dijk S; Bergman W; van Haeringen A; Silberg S; van Elderen TM; Tibben A
Psychooncology; 2005 Sep; 14(9):738-45. PubMed ID: 15744786
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
[TBL] [Abstract][Full Text] [Related]
4. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.
Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133
[TBL] [Abstract][Full Text] [Related]
5. Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study.
Kasparian NA; Meiser B; Butow PN; Soames Job RF; Mann GJ
Psychooncology; 2007 Jan; 16(1):69-78. PubMed ID: 16874747
[TBL] [Abstract][Full Text] [Related]
6. Clinical genetic testing for familial melanoma in Italy: a cooperative study.
Bruno W; Ghiorzo P; Battistuzzi L; Ascierto PA; Barile M; Gargiulo S; Gensini F; Gliori S; Guida M; Lombardo M; Manoukian S; Menin C; Nasti S; Origone P; Pasini B; Pastorino L; Peissel B; Pizzichetta MA; Queirolo P; Rodolfo M; Romanini A; Scaini MC; Testori A; Tibiletti MG; Turchetti D; Leachman SA; Bianchi Scarrà G;
J Am Acad Dermatol; 2009 Nov; 61(5):775-82. PubMed ID: 19500876
[TBL] [Abstract][Full Text] [Related]
7. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling.
Aspinwall LG; Leaf SL; Kohlmann W; Dola ER; Leachman SA
J Am Acad Dermatol; 2009 May; 60(5):745-57. PubMed ID: 19278751
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
9. Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study.
Bergenmar M; Hansson J; Brandberg Y
Eur J Oncol Nurs; 2009 Apr; 13(2):74-80. PubMed ID: 19179113
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
11. High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective.
Kasparian NA; Butow PN; Meiser B; Mann GJ
Psychooncology; 2008 Mar; 17(3):270-9. PubMed ID: 17600854
[TBL] [Abstract][Full Text] [Related]
12. Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma.
Nielsen K; Masback A; Bladstrom A; Lundgren L; Jonsson N; Borg A; Ingvar C; Olsson H
Br J Dermatol; 2008 Feb; 158(2):429-31. PubMed ID: 18047508
[No Abstract] [Full Text] [Related]
13. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland.
Debniak T; van de Wetering T; Scott R; Nagay L; Cybulski C; Górski B; Jakubowska A; Gronwald J; Masojć B; Huzarski T; Byrski T; Nej-Wołosiak K; Kładny J; Maleszka R; Lubinski J
Eur J Cancer Prev; 2008 Oct; 17(5):389-91. PubMed ID: 18714178
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
Rutter JL; Bromley CM; Goldstein AM; Elder DE; Holly EA; Guerry D; Hartge P; Struewing JP; Hogg D; Halpern A; Sagebiel RW; Tucker MA
Cancer; 2004 Dec; 101(12):2809-16. PubMed ID: 15529312
[TBL] [Abstract][Full Text] [Related]
15. Search for genetic variants associated with cutaneous malignant melanoma in the Ashkenazi Jewish population.
Loo JC; Paterson AD; Hao A; Shennan M; Peretz H; Sidi Y; Hogg D; Yakobson E
J Med Genet; 2005 May; 42(5):e30. PubMed ID: 15863662
[No Abstract] [Full Text] [Related]
16. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
[TBL] [Abstract][Full Text] [Related]
17. Predictors of psychological distress among individuals with a strong family history of malignant melanoma.
Kasparian NA; Meiser B; Butow PN; Simpson JM; Mann GJ
Clin Genet; 2008 Feb; 73(2):121-31. PubMed ID: 18177469
[TBL] [Abstract][Full Text] [Related]
18. Update of familial pancreatic cancer in Germany.
Bartsch DK; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Rieder H
Pancreatology; 2001; 1(5):510-6. PubMed ID: 12120230
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous melanoma: family screening and genetic testing.
Niendorf KB; Tsao H
Dermatol Ther; 2006; 19(1):1-8. PubMed ID: 16405564
[TBL] [Abstract][Full Text] [Related]
20. Management of familial melanoma and nonmelanoma skin cancer syndromes.
Santillan AA; Cherpelis BS; Glass LF; Sondak VK
Surg Oncol Clin N Am; 2009 Jan; 18(1):73-98, viii. PubMed ID: 19056043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
